Article
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Acta neuropathologica - 1 Jun 2021
Tesileanu C Mircea S, Vallentgoed Wies R, Sanson Marc, Taal Walter, Clement Paul M, Wick Wolfgang, Brandes Alba Ariela, Baurain Jean Francais, Chinot Olivier L, Wheeler Helen, Gill Sanjeev, Griffin Matthew, Rogers Leland, Rudà Roberta, Weller Michael, McBain Catherine, Reijneveld Jaap, Enting Roelien H, Caparrotti Francesca, Lesimple Thierry, Clenton Susan, Gijtenbeek Anja, Lim Elizabeth, de Vos Filip, Mulholland Paul J, Taphoorn Martin J B, de Heer Iris, Hoogstrate Youri, de Wit Maurice, Boggiani Lorenzo, Venneker Sanne, Oosting Jan, Bovée Judith V M G, Erridge Sara, Vogelbaum Michael A, Nowak Anna K, Mason Warren P, Kros Johan M, Wesseling Pieter, Aldape Ken, Jenkins Robert B, Dubbink Hendrikus J, Baumert Brigitta, Golfinopoulos Vassilis, Gorlia Thierry, van den Bent Martin, French Pim J
Abstract excerpt
Somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 occur at high frequency in several tumour types. Even though these mutations are confined to distinct hotspots, we show that gliomas are the only tumour type with an exceptionally high percentage of IDH1R132H mutations. Patients harbouring IDH1R132H mutated tumours have lower levels of genome-wide DNA-methylation, and an associated increased...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.